Syndax Pharmaceuticals (SNDX) Tops Q2 EPS by 13c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. SPCX
2. NVDA
3. NFLX
4. ISRG
5. TSLA
6. META
7. RTX
8. SMCI
9. GOOGL
10. S

Go back to Syndax Pharmaceuticals (SNDX) Tops Q2 EPS by 13c

Syndax Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Clinical and Business Update

August 7, 2018 4:06 PM EDT

WALTHAM, Mass., Aug. 7, 2018 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today reported its financial results for the second quarter ended June 30, 2018. In addition, the Company provided a clinical and business update. As of June 30, 2018, Syndax had $98.4 million in cash, cash equivalents and short-term investments.

"We made great progress across multiple programs during the first half of this year, including presentation of data from all three cohorts of ENCORE 601 and completion of target... More